Suppr超能文献

结合遗传学、定量脑 MRI 和认知测量改善从 MCI 到阿尔茨海默病进展的多模态预测。

Improved multimodal prediction of progression from MCI to Alzheimer's disease combining genetics with quantitative brain MRI and cognitive measures.

机构信息

Department of Neurosciences, University of California, San Diego, La Jolla, California, USA.

NORMENT Centre, Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.

出版信息

Alzheimers Dement. 2023 Nov;19(11):5151-5158. doi: 10.1002/alz.13112. Epub 2023 May 2.

Abstract

INTRODUCTION

There is a pressing need for non-invasive, cost-effective tools for early detection of Alzheimer's disease (AD).

METHODS

Using data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), Cox proportional models were conducted to develop a multimodal hazard score (MHS) combining age, a polygenic hazard score (PHS), brain atrophy, and memory to predict conversion from mild cognitive impairment (MCI) to dementia. Power calculations estimated required clinical trial sample sizes after hypothetical enrichment using the MHS. Cox regression determined predicted age of onset for AD pathology from the PHS.

RESULTS

The MHS predicted conversion from MCI to dementia (hazard ratio for 80th versus 20th percentile: 27.03). Models suggest that application of the MHS could reduce clinical trial sample sizes by 67%. The PHS alone predicted age of onset of amyloid and tau.

DISCUSSION

The MHS may improve early detection of AD for use in memory clinics or for clinical trial enrichment.

HIGHLIGHTS

A multimodal hazard score (MHS) combined age, genetics, brain atrophy, and memory. The MHS predicted time to conversion from mild cognitive impairment to dementia. MHS reduced hypothetical Alzheimer's disease (AD) clinical trial sample sizes by 67%. A polygenic hazard score predicted age of onset of AD neuropathology.

摘要

简介

目前迫切需要非侵入性、成本效益高的工具来早期检测阿尔茨海默病(AD)。

方法

使用来自阿尔茨海默病神经影像学倡议(ADNI)的数据,通过 Cox 比例模型构建了一个结合年龄、多基因风险评分(PHS)、脑萎缩和记忆的多模态风险评分(MHS),以预测从轻度认知障碍(MCI)向痴呆的转化。通过假设使用 MHS 进行富集,计算了需要的临床试验样本量。Cox 回归确定了 PHS 预测 AD 病理发生的年龄。

结果

MHS 预测了从 MCI 向痴呆的转化(第 80 百分位与第 20 百分位的风险比:27.03)。模型表明,MHS 的应用可以将临床试验样本量减少 67%。PHS 单独预测了淀粉样蛋白和 tau 的发病年龄。

讨论

MHS 可以提高 AD 的早期检测能力,用于记忆诊所或临床试验富集。

重点

多模态风险评分(MHS)结合了年龄、遗传学、脑萎缩和记忆。MHS 预测了从轻度认知障碍到痴呆的转化时间。MHS 将阿尔茨海默病(AD)临床试验样本量减少了 67%。多基因风险评分预测了 AD 神经病理学的发病年龄。

相似文献

4
Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.
Alzheimers Dement. 2017 Apr;13(4):e1-e85. doi: 10.1016/j.jalz.2016.11.007. Epub 2017 Mar 22.
5
Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition.
Acta Neuropathol. 2018 Jan;135(1):85-93. doi: 10.1007/s00401-017-1789-4. Epub 2017 Nov 24.
9
A parameter-efficient deep learning approach to predict conversion from mild cognitive impairment to Alzheimer's disease.
Neuroimage. 2019 Apr 1;189:276-287. doi: 10.1016/j.neuroimage.2019.01.031. Epub 2019 Jan 14.

引用本文的文献

2
Cross-Dataset Evaluation of Dementia Longitudinal Progression Prediction Models.
Hum Brain Mapp. 2025 Aug 1;46(11):e70280. doi: 10.1002/hbm.70280.
3
Cross-dataset Evaluation of Dementia Longitudinal Progression Prediction Models.
medRxiv. 2025 Jun 11:2024.11.18.24317513. doi: 10.1101/2024.11.18.24317513.
5
Neuroanatomical and clinical factors predicting future cognitive impairment.
Geroscience. 2025 Feb;47(1):915-934. doi: 10.1007/s11357-024-01310-0. Epub 2024 Aug 17.
6
Sex differences in the relationship between depression and Alzheimer's disease-mechanisms, genetics, and therapeutic opportunities.
Front Aging Neurosci. 2024 Jun 5;16:1301854. doi: 10.3389/fnagi.2024.1301854. eCollection 2024.

本文引用的文献

1
Lecanemab in Early Alzheimer's Disease.
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
2
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease.
Alzheimers Dement. 2022 Dec;18(12):2669-2686. doi: 10.1002/alz.12756. Epub 2022 Jul 31.
4
Alzheimer's Disease: Key Insights from Two Decades of Clinical Trial Failures.
J Alzheimers Dis. 2022;87(1):83-100. doi: 10.3233/JAD-215699.
5
A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease.
Nat Genet. 2021 Sep;53(9):1276-1282. doi: 10.1038/s41588-021-00921-z. Epub 2021 Sep 7.
6
Enriching the design of Alzheimer's disease clinical trials: Application of the polygenic hazard score and composite outcome measures.
Alzheimers Dement (N Y). 2020 Sep 13;6(1):e12071. doi: 10.1002/trc2.12071. eCollection 2020.
8
From Polygenic Scores to Precision Medicine in Alzheimer's Disease: A Systematic Review.
J Alzheimers Dis. 2020;74(4):1271-1283. doi: 10.3233/JAD-191233.
9
A comprehensive analysis of methods for assessing polygenic burden on Alzheimer's disease pathology and risk beyond .
Brain Commun. 2020;2(1):fcz047. doi: 10.1093/braincomms/fcz047. Epub 2019 Dec 16.
10
Friend, Foe or Both? Immune Activity in Alzheimer's Disease.
Front Aging Neurosci. 2019 Dec 10;11:337. doi: 10.3389/fnagi.2019.00337. eCollection 2019.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验